| scholarly article | Q13442814 |
| P356 | DOI | 10.1093/ANNONC/MDP549 |
| P698 | PubMed publication ID | 19940007 |
| P50 | author | Josep Tabernero Caturla | Q37387600 |
| Fortunato Ciardiello | Q43184447 | ||
| Francisco J Ramos | Q77833971 | ||
| P2093 | author name string | F Rivera | |
| J Baselga | |||
| A Cervantes | |||
| T Macarulla | |||
| E Martinelli | |||
| S Roselló | |||
| S Liebscher | |||
| O Kisker | |||
| E Rodriguez-Braun | |||
| M E Vega-Villegas | |||
| P2860 | cites work | Nonparametric Estimation from Incomplete Observations | Q25938997 |
| Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. | Q27824811 | ||
| Cetuximab for the treatment of colorectal cancer. | Q27851419 | ||
| Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer | Q28240089 | ||
| Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer | Q28305293 | ||
| Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer | Q29616236 | ||
| Biweekly cetuximab and irinotecan in advanced colorectal cancer patients progressing after at least one previous line of chemotherapy: results of a phase II single institution trial. | Q36858054 | ||
| Cetuximab in combination with irinotecan/5-fluorouracil/folinic acid (FOLFIRI) in the initial treatment of metastatic colorectal cancer: a multicentre two-part phase I/II study | Q37182234 | ||
| Structural basis for inhibition of the epidermal growth factor receptor by cetuximab | Q45345151 | ||
| FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. | Q45949257 | ||
| Pharmacokinetic profile of cetuximab (Erbitux) alone and in combination with irinotecan in patients with advanced EGFR-positive adenocarcinoma | Q46624336 | ||
| EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer | Q46662707 | ||
| Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracil | Q46748546 | ||
| Cetuximab and irinotecan/5-fluorouracil/folinic acid is a safe combination for the first-line treatment of patients with epidermal growth factor receptor expressing metastatic colorectal carcinoma | Q46816802 | ||
| P433 | issue | 7 | |
| P921 | main subject | colorectal cancer | Q188874 |
| pharmacodynamics | Q725307 | ||
| pharmacokinetics | Q323936 | ||
| cetuximab | Q420296 | ||
| colorectal carcinoma | Q25493920 | ||
| metastatic colon cancer | Q108566365 | ||
| P304 | page(s) | 1537-1545 | |
| P577 | publication date | 2009-11-25 | |
| P1433 | published in | Annals of Oncology | Q326122 |
| P1476 | title | Cetuximab administered once every second week to patients with metastatic colorectal cancer: a two-part pharmacokinetic/pharmacodynamic phase I dose-escalation study | |
| P478 | volume | 21 |
| Q47121100 | A randomized phase II study of cetuximab every 2 weeks at either 500 or 750 mg/m2 for patients with recurrent or metastatic head and neck squamous cell cancer |
| Q36907279 | Alternate dosing of cetuximab for patients with metastatic colorectal cancer |
| Q36914483 | Analysis of Impact of Post-Treatment Biopsies in Phase I Clinical Trials. |
| Q83964468 | Anti-EGFR (cetuximab) combined with irinotecan for treatment of elderly patients with metastatic colorectal cancer (mCRC) |
| Q38650454 | Anti-EGFR monoclonal antibody panitumumab for the treatment of patients with metastatic colorectal cancer: an overview of current practice and future perspectives. |
| Q34052270 | Biweekly cetuximab and first-line chemotherapy in chinese patients with k-ras wild-type colorectal cancers |
| Q34610252 | Biweekly cetuximab in combination with FOLFOX-4 in the first-line treatment of wild-type KRAS metastatic colorectal cancer: final results of a phase II, open-label, clinical trial (OPTIMIX-ACROSS Study). |
| Q43885266 | Biweekly cetuximab plus FOLFIRI/irinotecan as first/second-line chemotherapy for patients with KRAS wild-type metastatic colorectal cancer: a retrospective analysis in Southwest Chinese population |
| Q54578867 | Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status. |
| Q90734623 | Distinguishing Features of Cetuximab and Panitumumab in Colorectal Cancer and Other Solid Tumors |
| Q38661133 | Exposure-response relationship of ramucirumab in patients with advanced second-line colorectal cancer: exploratory analysis of the RAISE trial |
| Q44240338 | FOLFOX4 plus cetuximab administered weekly or every second week in the first-line treatment of patients with KRAS wild-type metastatic colorectal cancer: a randomized phase II CECOG study |
| Q33775197 | First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study. |
| Q30317428 | Gemcitabine and oxaliplatin with or without cetuximab in advanced biliary-tract cancer (BINGO): a randomised, open-label, non-comparative phase 2 trial. |
| Q28285473 | KRAS gene amplification in colorectal cancer and impact on response to EGFR-targeted therapy |
| Q90416901 | Machine Learning Analysis of Individual Tumor Lesions in Four Metastatic Colorectal Cancer Clinical Studies: Linking Tumor Heterogeneity to Overall Survival |
| Q35807573 | Multicenter Phase II study of FOLFOX or biweekly XELOX and Erbitux (cetuximab) as first-line therapy in patients with wild-type KRAS/BRAF metastatic colorectal cancer: The FLEET study. |
| Q37701250 | Multicenter phase II study of infusional 5-fluorouracil (5-FU), leucovorin, and oxaliplatin, plus biweekly cetuximab as first-line treatment in patients with metastatic colorectal cancer (CELINE trial). |
| Q46735002 | Panitumumab and irinotecan every 3 weeks is an active and convenient regimen for second-line treatment of patients with wild-type K-RAS metastatic colorectal cancer |
| Q82973963 | Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines |
| Q89122613 | Phase II trial of biweekly cetuximab and irinotecan as third-line therapy for pretreated KRAS exon 2 wild-type colorectal cancer |
| Q46523280 | Physiologically-based pharmacokinetic modeling to predict the clinical pharmacokinetics of monoclonal antibodies. |
| Q49468322 | Potential Influence of Endothelial Adsorption on the Delayed Time to Maximum Concentration of Biopharmaceuticals |
| Q46253386 | Prospective study of EGFR intron 1 (CA)n repeats variants as predictors of benefit from cetuximab and irinotecan in chemo-refractory metastatic colorectal cancer (mCRC) patients |
| Q91216118 | Rationale and budget impact of bimonthly use of Cetuximab in patients with recurrent and/or metastatic head and neck cancer |
| Q50041876 | Strategies for clinical development of monoclonal antibodies beyond first-in-human trials: tested doses and rationale for dose selection |
| Q34205052 | Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab. |
| Q38880745 | The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets |
| Q43745972 | Weekly and every 2 weeks cetuximab maintenance therapy after platinum-based chemotherapy plus cetuximab as first-line treatment for non-small cell lung cancer: randomized non-comparative phase IIIb NEXT trial |
Search more.